Geron sells stem cells by the seashore in structured deal with BioTime
This article was originally published in Clinica
Executive Summary
One year after Geron announced that it would end development of its human embryonic stem cell therapy for spinal cord injuries, the company has agreed to transfer the assets to BioTime. The latter made an unsolicited offer to take the discontinued program off Geron's hands in October (www.clinica.co.uk, 23 October 2012).